VEGF-D Antibody (28AT743.288.48): sc-517375

VEGF-D Antibody (28AT743.288.48) is a mouse monoclonal IgG1 antibody that detects VEGF-D in mouse, rat, and human samples through western blotting (WB). VEGF-D, a member of the vascular endothelial growth factor family, plays a crucial role in angiogenesis, which is the formation of new blood vessels from pre-existing ones, a process vital for tumor growth and metastasis. VEGF-D is primarily located in the extracellular space, where VEGF-D interacts with specific receptors on endothelial cells to promote their proliferation and migration, thereby facilitating the development of new blood vessels. This function is particularly important in cancer, as tumors often exploit angiogenesis to secure a blood supply that supports growth and spread. Notably, VEGF-D exists in multiple isoforms, and VEGF-D expression can be induced by various oncogenic factors, including c-Fos, which is implicated in the transition of early-stage tumors to more aggressive forms. The presence of eight cysteine residues in the central region of VEGF-D is essential for homodimerization, a structural feature critical for biological activity and receptor interaction. Using anti-VEGF-D antibody (28AT743.288.48) in research can provide valuable insights into tumor angiogenesis mechanisms and potential therapeutic targets within this pathway.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VEGF-D Antibody (28AT743.288.48) References:

1. Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas.  |  Pazgal, I., et al. 2007. Leuk Lymphoma. 48: 2213-20. PMID: 17926187
2. Vascular endothelial growth factor (VEGF)-D stimulates VEGF-A, stanniocalcin-1, and neuropilin-2 and has potent angiogenic effects.  |  Jauhiainen, S., et al. 2011. Arterioscler Thromb Vasc Biol. 31: 1617-24. PMID: 21474827
3. VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis.  |  Maa, HC., et al. 2015. Appl Immunohistochem Mol Morphol. 23: 209-14. PMID: 25221955
4. PC4 induces lymphangiogenesis dependent VEGF-C/VEGF-D/VEGFR-3 axis activation in lung adenocarcinoma.  |  Tao, S., et al. 2015. Am J Cancer Res. 5: 1878-89. PMID: 26269750
5. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.  |  Eroğlu, A., et al. 2017. Adv Clin Exp Med. 26: 245-249. PMID: 28791841
6. Analyses of VEGFC/VEGF-D expressions, density and endothelial lymphatic proliferation in salivary gland neoplasms.  |  Barroso, KMA., et al. 2020. Exp Mol Pathol. 113: 104385. PMID: 32004508
7. VEGF-D: a novel biomarker for detection of COVID-19 progression.  |  Kong, Y., et al. 2020. Crit Care. 24: 373. PMID: 32576222
8. circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFβR1/VEGF-D signaling.  |  Zhu, J., et al. 2021. Mol Ther. 29: 1838-1852. PMID: 33545359
9. Dysregulated Serum Lipid Metabolism Promotes the Occurrence and Development of Diabetic Retinopathy Associated With Upregulated Circulating Levels of VEGF-A, VEGF-D, and PlGF.  |  Zhang, X., et al. 2021. Front Med (Lausanne). 8: 779413. PMID: 34904074
10. VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients.  |  Ravaggi, A., et al. 2022. Front Oncol. 12: 818613. PMID: 35463308

The preferred VEGF-D antibody is VEGF-D Antibody (C-12): sc-373866.